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Summary 
Pax3 RNA is expressed in neural crest when Schwann 
cell (SC) precursors migrate to the PNS, Pax3 RNA and 
SC markers were monitored in sciatic nerves of mice 
during development and nerve repair. An inverse cor- 
relation was observed between expression of Pax3 
RNA and myelin basic protein (MBP). inverse correla- 
tion was also observed in SC primary cultures. Treat- 
ing cultures with forskolin, an adenylate cyclase ago- 
nist, repressed Pax3 RNA, GFAP, NGFR, N-CAM, and 
L1 and elevated MBP. Subsequent microinjection with 
Pax3 expression vector elevated Pax3 RNA, GFAP, 
NGFR, N-CAM, and L1 and repressed MBP. Thus, Pax3 
is likely involved in the differentiation pathway to my- 
elinating SCs. Pax3 repressed a 1.3 kb MBP promoter 
fragment in cotransfection assays, suggesting that it 
represses MBP transcription. 
Introduction 
Many events in neural development are mediated through 
cell-cell interactions. In vertebrates, a particularly striking 
example is provided by the interaction of neurons and 
gila, which leads to the formation of myelin, the insulating 
sheath that surrounds all rapidly conducting axons (Ritch- 
ie, 1984). This specialized cell type is elaborated postna- 
tally, by oligodendrocytes in the CNS and by Schwann 
cells (SCs) in the PNS. Neurons and SCs exchange signals 
during development, maintenance, degeneration, and re- 
generation processes. SC development can be consid- 
ered in two stages. First, S-100-positive, embryonic SCs 
(eSCs) are generated from S-100-negative precursor SCs 
of the neural crest (stage 1 differentiation) by a process 
involving migration and proliferation. Second, eSCs are 
terminally differentiated (stage 2 differentiation) into the 
nonproliferative myelinating SCs (mSCs) found in adult 
nerves. The nonmyelinating SCs (nmSCs) found in adult 
nerves closely resemble eSCs in morphology and molecu- 
lar markers (Webster and Favilla, 1984; Bunge et al., 1986; 
Mirsky and Jessen, 1990; Jessen and Mirsky, 1991). 
Understanding of peripheral nerve maturation has been 
aided by analysis of prenatal SC development with pan- 
els of molecular markers (Jessen et al., 1990). A well- 
characterized set of differentiation markers is used to mon- 
itor this development closely (Mirsky et al., 1990; Mirsky 
and Jessen, 1990; Martini and Schachner, 1986; Snipes 
et al., 1992). Induction and maintenance of myelin-specific 
gene expression is dependent upon axonal contact. Axons 
must provide some signal(s) that activates second mes- 
senger cascades in SCs. As a consequence, SCs with- 
draw from the cell cycle and express myelin-specific genes 
(Lemke and Axel, 1985; Lemke and Chao, 1988; Trapp 
et al., 1988). 
When mSCs are withdrawn from axonal contact, either 
by peripheral nerve transection in vivo (Trapp et al., 1988) 
or through culture in vitro (Lemke and Chao, 1988), the 
levels of myelin-specific mRNAs are dramatically reduced. 
In vitro, the molecular phenotype (expression levels of SC 
marker proteins such as P0, neural cell adhesion molecule 
[N-CAM], L1, nerve growth factor receptor [NGFR], glial 
fibrillary acidic protein [GFAP], myelin basic protein [MBP], 
and S-100) associated with axonal contact can largely be 
simulated by agents that elevate the intracellular concen- 
tration of cAMP (e.g., forskolin; Lemke and Chao, 1988; 
Lemke, 1988). The myelin proteins P0 and MBP are each 
up-regulated by forskolin treatment. At both the mRNA 
and protein levels, the ratio of MBP to P0 is similar in cAMP- 
treated cultures (in vitro) (Morgan et al., 1991) and in mSCs 
in contact with axons (in vivo) (Lemke and Chao, 1988; 
Lemke, 1988). In both systems, cAMP-mediated up-regu- 
lation of the myelin proteins is followed by down-regulation 
of NGFR, GFAP, and some members of the immunoglobu- 
l ingene superfamily, such as L1 and N-CAM (Morgan et 
al., 1991). 
Pax3, a member of the murine paired box gene family, 
encodes a 479 amino acid protein containing both a paired 
domain and a paired-type homeodomain (Goulding et al., 
1991). It acts as a sequence-specific DNA-binding protein 
(Goulding et al., 1991 ; Chalepakis et al., 1994a) and regu- 
lates gene expression (Chalepakis et al., 1994a, 1994b). 
The splotch allele has a deletion in the homeodomain (Ep- 
stein et al., 1991 ), whereas the splotch delayed(spd) allele 
has a point mutation in the paired domain of the Pax3 gene 
(Moase and Trasler, 1990). Both mutations likely affect the 
DNA binding properties of the protein in different ways yet 
still produce Pax3 RNA. Pax3 RNA is expressed in the 
dorsal part of the neuroepithelium, in neural crest deriva- 
tives, and in somitic mesoderm (Goulding et al., 1991). 
Neural crest cells that migrate along the axons of the 
PNS become precursor SCs and, upon expression of 
S-100, are named eSCs (Jessen et al., 1987). In wild-type 
mice, S-100-positive cells are detected between embry- 
onic day (E) 13.5 and birth. Homozygous splotch mice die 
at E13.5. No S-100-positive cells were detected at this 
stage (data not shown). However, in homozygotes of the 
spd allele, which survive until E18.5 (Moase and Trasler, 
1990), a very small number of S-100-positive glial cells 
could occasionally be detected along the sciatic nerve at 
E13.5; 2 days later, S-100-positive cells were no longer 
detected (data not shown), and eSCs are no longer ob- 
served in these mutants (Franz, 1990). Thus, dysfunc- 
tional Pax3 is associated with variable reduction of the SC 
lineage in the sciatic nerve. S-100 could occasionally be 
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turned on in the absence of fully functional Pax3, but levels 
were not maintained before spd homozygotes died, sug- 
gesting that Pax3 functions both in maintaining and estab- 
lishing the S-100-positive phenotype. 
In this report, we describe Pax3 RNA expression in the 
SCs of developing and regenerating mouse sciatic nerves 
and establish an inverse correlation between MBP and 
Pax3 RNA expression. Immunofluorescent double label- 
ing for Pax3 RNA and cell-specific protein markers in de- 
generating and regenerating sciatic nerve suggests that 
Pax3 expression depends on axon-SC interaction. In cul- 
tured SCs, Pax3 RNA and nmSC marker proteins are ex- 
pressed, but MBP is not. Forskolin inverts this molecular 
phenotype. Subsequent injection of Pax3 expression vec- 
tors causes a rereversal of MBP and nmSC marker protein 
expression. Cotransfection experiments with Pax3 ex- 
pression vectors and a reporter plasmid containing 1.3 kb 
of the M BP promoter upstream of lacZ (MBP-lacZ) demon- 
strated that the MBP promoter can be down-regulated by 
Pax3 RNA expression. 
Results 
Pax3 RNA Expression in Schwann Cells 
during PNS Development 
Closure of the neural fold gives rise to neural crest cells 
that migrate into the PNS. In E8.5 mouse embryos, Pax3 
RNA is expressed in those regions of the neural tube from 
which the neural crest cells will migrate (Goulding et al., 
1991). The axons of the embryonic sciatic nerve are ac- 
companied by SC precursors (S-100-negative) derived 
from neural crest cells. As the embryos approach birth, 
eSCs (S-100-positive) differentiate from the precursors. 
Teased nerve preparations of embryonic, early postna- 
tal, and adult mouse sciatic nerve were examined to deter- 
mine which cells of the sciatic nerve express Pax3 RNA. 
This method separates the individual fibers of the nerve, 
thereby exposing SCs. Immunochemical characterization 
of the glia in these preparations was performed with anti- 
bodies against S-100 (Brockes et al., 1979), GFAP, and 
MBP proteins, typical SC markers. 
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Figure 1. Pax3 RNA and Schwan  Cell Marker 
Proteins at Various Developmental Stages 
Double-labeling in situ hybridization was per- 
formed with a DIG-Pax3 RNA probe (green) 
and antibodies against S-100 (C) or GFAP (F 
and I) proteins (red) in teased nerve prepara- 
tions from the sciatic nerve of E14.5 mouse 
embryos (A-C) and P5 mice (D-F) and from 
the cervical sympathetic trunk of young adult 
mice (P30; G-I). Left panels (A, D, and G) are 
phase-contrast images. Fluorescein-labeled 
anti-DIG antibody was used to detect the DIG- 
Pax3 RNA probe (B, E, and H), and rhodamine- 
labeled secondary antibody was used to visual- 
ize anti-S-100 and anti-GFAP antibodies (C, F, 
and I). All SCs in the sciatic nerve of E14.5 
embryos (S-100-positive) were positive for 
Pax3 RNA. Later in development, only nmSCs 
(GFAP-positive) expressed Pax3 RNA. GFAP- 
negative cells are also Pax3 negative. All mSCs 
were Pax3 negative (data not shown). Bar, 
20 ~m. 
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In the mouse, S-100 protein was first expressed in cells 
along the axons at E14, indicating the emergence of eSCs 
from precursor neural crest derivatives (rat E16; Jessen 
and Mirsky, 1991). Immunofluorescent double labeling for 
Pax3 RNA and S-100 protein in teased sciatic nerve prepa- 
rations of E14.5 embryos showed that Pax3 RNA was ex- 
pressed in all eSCs (Figures 1A-1C). 
At later time points, GFAP was used as a specific marker 
for nmSCs (Figure 2B), and MBP or Gal-c were used as 
specific markers for mSCs. Teased sciatic nerves of post- 
natal day (P) 5 mice showed Pax3 RNA in GFAP-positive 
SCs (see Figures 1D-1F). No Pax3 RNA signal was ob- 
served in mSCs at this stage (data not shown). 
In the postnatal period, between P5 and P30, SCs un- 
dergo radical changes in morphology and molecular ex- 
pression that result in either the formation of a myelin 
sheath or the enclosure of axons to form unmyelinated 
fibers. In situ fluorescence of teased nerve preparations 
at P30 (adult), when myelination is largely completed, 
showed that Pax3 RNA was associated with nmSCs (Fig- 
ures 2A-2C) and not with mSCs (Figures 3G-31). More 
than 70% of the axons in the adult sciatic nerve were 
myelinated and showed no significant Pax3 RNA signal 
(Figures 3G-31i. In contrast, SCs of the adult cervical sym- 
pathetic trunk (see Figures 1G-11), in which 99% of the 
axons are nonmyelinated, were Pax3 RNA positive (see 
Figure 1H). These SCs are also GFAP positive (see Figure 
B 
D 
1 I). In summary, Pax3 RNA was present in eSCs and ma- 
ture nmSCs, but was down-regulated inmature mSCs dur- 
ing development. 
Pax3 RNA Down-Regulation Is Axon 
Dependent and Reversible 
To test whether down-regulation of Pax3 RNA during my- 
elination depends on continuous contact with axons, de- 
generation and regeneration experiments were used 
(Trapp et al., 1988). The sciatic nerves of P30 mice were 
cut or crushed. Teased axons of the distal side were ana- 
lyzed from 1 to 60 days by immunostaining for Pax3 RNA 
and cell type-specific protein markers. After 1 month, no 
more myelin fibers remained, and the nerve was com- 
pletely degenerated. In nerve crush experiments, the 
nerve was completely regenerated by 60 days. In the proxi- 
mal nerve stump, in which myelin remains intact, Pax3 
RNA expression was observed only in nmSCs throughout 
the time course (data not shown). 
In the adult sciatic nerve, Pax3 RNA was always de- 
tected in nmSCs (see Figures 2A-2C) but was absent in 
mSCs. Pax3 RNA expression in mSCs was up-regulated 
between 3 and 4 days after lesion (see Figures 2D-2G), 
with the highest expression levels near the onset of up- 
regulation. Demyelination was already apparent at this 
time. In a time course analysis, with time points at 3, 4, 
5, 7, 15, 30, and 60 days, the induction of Pax3 RNA in 
Figure 2. Pax3 RNA Induction i  mSCs 4 Days 
after Sciatic Nerve Transection 
Double-labeling in situ hybridization was per- 
formed with a DIG-Pax3 RNA probe (green) 
and an antibody against GFAP protein (red) in 
transected sciatic nerve preparations of P30 
mice (A-C, uncut control; D and E, distal stump 
4 days postcut; F and G, distal stump 7 days 
postcut). Right panels (C, E, and G) are phase- 
contrast images. Fluorescein-labeled anti-DIG 
antibody was used to detect he DIG-Pax3 
RNA probe (A, D, and F), and rhodamine- 
labeled secondary antibody was used to visual- 
ize anti-GFAP antibody (B). Pax3 RNA is ex- 
pressed in untreated, GFAP-positive nmSCs 
(A-C). mSCs of this preparation showed no sig- 
nal (data not shown). Bar, 20 ~.m. 
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mSCs was followed by induction of eSC markers such as 
GFAP, N-CAM, L1, and NGFR and by down-regulation of 
MBP and Po (data not shown). 
To determine whether Pax3 RNA expression in SOs 
would be repressed again as a result of axonal regenera- 
tion, the sciatic nerve was crushed (Scherer et al., 1994). 
From the previous results obtained by nerve transection, it 
was clear that the myelinated fibers undergoing Wallerian 
degeneration lost MBP and gained Pax3 RNA expression 
between days 3 and 4 (see Figure 2D) after lesion. This 
was also the case with crushed nerves (Figures 3A and 
3B). Crushing results in degeneration of nerve axons distal 
to the crush point, with subsequent regeneration. In rat, 
degeneration takes 7-12 days, and regeneration starts 
after 15 days (Scherer et al., 1994). In mouse, remyelina- 
tion of regenerating axons tarted after 7 days. At this 
stage, the SCs just begin to produce and store myelin 
(Lemke, 1988) and showed high levels of Pax3 RNA (Fig- 
ures 3C and 3D). After an additional week, such myelinat- 
ing SCs on regenerating axons (Figures 3E and 3F) 
c 
4 
E 
G 
showed very low Pax3 RNA signals, which then disap- 
peared completely as myelination was completed. Sup- 
pression of Pax3 RNA expression in the reinnervating dis- 
tal nerve segment following nerve crush injury suggested 
that Pax3 RNA was down-regulated in SCs by axonal con- 
tact. A parallel im munocytochemical study with antibodies 
recognizing NGFR, L1, N-CAM and GFAP showed that 
these markers also undergo transient increases between 
crushing and regeneration (data not shown). In particular, 
L1 was induced at the same time as Pax3 RNA (3 days). 
For comparison, NGFR, N-CAM, and GFAP were induced 
at 5, 5, and 4 days, respectively. Transient induction of 
Pax3 RNA after lesion of the adult sciatic nerve suggested 
that this gene plays a role in nerve repair. The inverse 
correlation between MBP and Pax3 RNA expression sug- 
gested that Pax3 may suppress MBP gene expression. 
Pax3 RNA Expression in Cultured Schwann Cells 
To test whether the expression patterns observed in vivo 
could be recapitulated in vitro, Pax3 RNA expression was 
H 
Figure 3. RegenerationRevertsthePax3RNA 
Induction Caused by Nerve Crushing 
Double-labeling insitu hybridization was per- 
formed with a DIG-Pax3 RNA probe (green) 
and an antibody against GFAP protein (red) in
the distal stump of crushed sciatic nerves of 
P30 mice (A and B, 4 days postcrush; C and 
D, 7 days postcrush; E and F, 15 days post- 
crush; G-I, 60 days postcrush). Right panels 
(B, D, F, and I) are phase-contrast images. Flu- 
orescein-labeled anti-DIG antibody was used 
to detect the DIG-Pax3 RNA probe (A, C, E, 
and G), and rhodamine-labeled secondary anti- 
body was used to visualize anti-GFAP antibody 
(H). Pax3 RNA was always expressed in GFAP- 
positive nmSCs (data not shown). At 4 (A and 
B) and 7 (C and D) days after crushing, Pax3 
RNA was expressed by degenerating mSCs 
(arrowheads). At 15 days postcrush (E and F), 
Pax3 RNA was expressed only by the nmSCs 
(two arrowheads) and not by the regenerated 
mSCs (single arrowhead). At 60 days post- 
crush (G-I), the nerve was regenerated, and 
Pax3 RNA was expressed only in GFAP- 
positive SCs (nmSCs), as in untreated sciatic 
nerves. Bar, 10 p.m. 
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studied in primary SC cultures from dissociated sciatic 
nerves. SC cultures were prepared from P5 mouse sciatic 
nerves. Shortly after plating, cultured SCs have a short, 
condensed morphology (Figure 4A) and express protein 
markers characteristic of eSCs (S-100; Figure 4C) or adult 
nmSCs (GFAP and NGFR; data not shown). After a further 
4 days in serum-free defined medium, SCs lost their con- 
densed morphology and had long bipolar protrusions ex- 
tending from the cell body (Figure 4D). The same markers 
were still expressed (S-100, GFAP, and NGFR; data not 
shown). Pax3 RNA was expressed at both early (Figure 
4B) and late (Figure 4E) times after plating. MBP or Po 
was not detected at any time (data not shown). 
Thus, with respect to the SC marker proteins, cultured 
SCs have the molecular phenotype of eSCs or adult 
nmSCs of the normal animal. This molecular phenotype 
predominates in SC populations during the Wallerian de- 
generation-regeneration transition. At later stages in re- 
generation, the second molecular phenotype, character- 
ized by MBP expression and Pax3 RNA suppression, 
predominates. 
Pax3 Represses MBP and Activates 
Four nmSC Protein Markers 
Forskolin treatment was used to mimic the second molecu- 
lar phenotype (axon-dependent, MBP-positive) in a cul- 
tured system. Cultured rat neonatal SCs do not express 
myelin genes (Lemke and Chao, 1988), presumably be- 
cause of the withdrawal from axonal contact. MBP gene 
expression is turned on by agents such as forskolin, which 
raise intracellular levels of cAM P (Lem ke and Chao, 1988). 
In culture, the effect of axonal presence is mimicked by 
elevation of intracellular cAMP levels. 
Dissociated SCs from P5 mouse sciatic nerve, after 48 
hr in vitro, were treated with 2 I~M forskolin for a further 
48 hr. Forskolin treatment resulted in a marked increase 
of MBP (Figure 5C) and a down-regulation ofGFAP, N-CAM, 
L1, and NGFR (data not shown). As expected, Pax3 RNA 
was not or very weakly detectable in MBP-positive SCs 
(Figure 5B). Thus, as cAMP levels were elevated by for- 
skolin, the levels of Pax3 RNA (compare Figures 4B and 
4E with Figure 5B) and four nmSC marker proteins de- 
clined. In contrast, MBP levels increased (Figure 5C), and 
S-100 levels were unaffected (data not shown). Therefore, 
cAMP elevation in culture mimicked qualitatively the "axo- 
nal presence" of regeneration experiments, insofar as 
Pax3 RNA, MBP, GFAP, N-CAM, L1, NGFR, and S-100 
molecular phenotypes are concerned. It is not surprising 
that so many genes alter their expression (in opposite di- 
rections) in response to an agent such as forskolin, which 
is known to interfere at the level of second messenger 
metabolism. 
Microinjection experiments were performed to test 
whether ectopic Pax3 DNA production could suppress for- 
skolin-induced MBP expression. Cultured SCs were mi- 
croinjected after 48 hr in forskolin (Table 1). Plasmids or 
buffer was microinjected into SC nuclei. After 24 hr, - 50% 
of the injected cells had survived and had characteristic 
enlarged nuclei due to injection (Figures 5D, 5G, 5J, 5M, 
and 5P). Cells were fixed and analyzed by double-labeling 
in situ hybridization with a Pax3 RNA probe (green; Figures 
5E, 5H, 5K, 5N, and 5Q) and one of six antibodies to 
marker proteins (red; Figures 5C, 5F, 51, 5L, 50, 5R). For 
example, 30 cells injected with SV40-Pax3 survived 24 
hr (Table 1). All were analyzed and found to be positive 
for Pax3 RNA (Figures 5E, 5H, 5K, and 5N); 27 were also 
analyzed for one of the six marker proteins; 12 were ana- 
lyzed for MBP (Figure 5F); and 3 were analyzed for each 
of the other five protein markers (Table 1; Figures 51 
[GFAP], 5L [NGFR], and 50 [N-CAM]; data not shown 
for L1 and $100). Mock injections with control plasmid 
(SV40-only; Figures 5P-5R) or buffer (data not shown) 
were performed to control for artifacts due to the expres- 
sion vector or injection procedure, respectively. To ensure 
that effects observed with SV40-Pax3 were not due 
merely to the overexpression of any transcription factor, 
B C 
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Figure 4. Cultured Schwann Cells Express 
Pax3 RNA and S-100 
Cell cultures were prepared from dissociated 
sciatic nerves of P5 mice. After 3 hr (A-C) or 
4 days (D and E) in culture, double-labeling in 
situ hybridization was performed with a DIG- 
Pax3 RNA probe (green) and an antibody 
against S-100 protein (red). Fluorescein- 
labeled anti-DIG antibody was used to detect 
the DIG-Pax3 RNA probe (B and E), and rhoda- 
mine-labeled secondary antibody was used to 
visualize anti-S-100 antibody (C). Phase- 
contrast micrographs depict he morphology in
short- (A) and long- (D) term cultures. Pax3 RNA 
was expressed by SCs in short- (B) and long- 
(E) term cultures, Bar, 20 ~m. 
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mock injections with SV40-Hoxa7 and CMV-Hoxa7 ex- 
pression vectors were performed. The functionality of 
these plasmids was demonstrated previously (Maulbecker 
and Gruss, 1993). Forskolin-treated, SV40-Pax3-injected 
SCs gave a higher Pax3 RNA signal than untreated SCs, 
suggesting that greater than physiological doses of Pax3 
RNA were present in these experiments. 
The injection data (Figure 5; Table 1) clearly demon- 
strate that MBP expression was down-regulated by SV40-  
Pax3 injection (all 12 were negative; Figure 5F) but was 
unaffected by all mock injections (all 50 were positive; 
Figure 5R). In addition, they suggest that NGFR (Figure 
5L), GFAP (Figure 51), L1 (data not shown), and N-CAM 
(Figure 50)  responded in an opposite mannertoPax3 DNA 
injection, being activated rather than repressed. Only 3 
SV40-Pax3-injected cells were analyzed for each of these 
proteins, and all were positive. Levels detected were simi- 
lar to those seen prior to forskolin treatment. For each of 
these four protein markers, all 7 mock-injected cells (11 
for NGFR) were negative. The S-100 protein marker be- 
haved the same in SV40-Pax3 and mock injections, indi- 
cating that not all genes are affected by SV40-Pax3 injec- 
tion. Together, these results demonstrate that ectopic 
Figure 5. Microinjection of Pax3 Expression 
Vectors Inverts Expression of Schwann Cell 
Marker Proteins 
Cultured SCs from the sciatic nerves of P5 mice 
were treated with forskolin, which makes them 
Pax3 RNA negative (B) and MBP positive (C). 
Cells were microinjected with SV40-Pax3 
(D-O) or SV40-only (P-R). After 24 hr, cells 
were fixed and analyzed by double-labeling in 
situ hybridization to detect Pax3 RNA (green) 
and one of four SC marker proteins (red). Pri- 
mary antibodies against MBP (C, F, and R), 
GFAP (I), NGFR (L), and N-CAM (O) were visu- 
alized by a rhodamine-labeled secondary anti- 
body. The DIG-Pax3 RNA probe was detected 
by a fluorescein-labeled anti-DIG antibody. Up- 
per panels show phase-contrast micrographs 
before (A) and after (D, G, J, M, and P) microin- 
jection. Injection of SV40-Pax3 results in Pax3 
RNA expression (E-N), whereas mock injec- 
tion leads to no detectable Pax3 RNA (Q). Ex- 
pression of Pax3 RNA results in reduction of 
MBP protein (F) and elevation of GFAP (I), 
NGFR (L), and N-CAM (O) protein levels, Bar, 
10 ~m. 
Pax3 DNA expression causes MBP down-regulation and 
also induces the four marker proteins NGFR, GFAP, L1, 
and N-CAM It remains to be seen whether regulation of 
all five markers by Pax3 occurs by direct mechanisms, 
such as binding of Pax3 to all five promoters, or by an 
indirect mechanism, such as interference with second 
messenger metabolism. 
Pax3 Inhibits MBP Promoter Activity 
Cotransfection assays were used to investigate whether 
the inverse correlation between Pax3 and MBP expression 
was due to inhibition of MBP promoter function by Pax3. 
N-2A (neuroblastoma) cells were cultured in DMEM sup- 
plemented with 10% fetal calf serum. The reporter plas- 
mid, pBGlb  (Miura et al., 1989; Okano et al., 1988), con- 
tains 1.3 kb of MBP promoter fused to trpS/lacZ. A control 
reporter contains the RSV-LTR upstream of lacZ. Report- 
ers were cotransfected with CMV-Pax3, CMV-Pax6, and 
CMV-only effector plasmids. After 48 hr, cells were har- 
vested and assayed for reporter activity. 
The weight ratio of effector to reporter plasmid was sys- 
tematically altered in a range from 0.02 to 0.4 to minimize 
the effector to reporter ratio. The CMV-Pax3 effector sig- 
Table 1. Microinjection Summary 
SV40-Pax3 SV40-only Buffer SV40-Hoxa7 CMV-Hoxa7 
Molecular Markers Inj + Inj + Inj + Inj + Inj + 
Pax3 RNA 30 30 40 0 34 1 24 0 17 0 
MBP 12 0 20 20 10 10 10 10 10 10 
NGFR 3 3 5 0 3 1 2 0 1 0 
GFAP 3 3 2 0 2 0 2 0 1 0 
L1 3 3 2 0 2 0 2 0 1 0 
N-CAM 3 3 2 0 2 0 2 0 1 0 
S-100 3 3 4 4 2 2 2 2 2 2 
Molecular markers were detected by a DIG-Pax3 RNA probe or by antibodies against he proteins. For injected material, 3-6 pg of circular plasmid 
was injected per cell. For each injection, the number of cells that survived for 24 hr (In j) and the number that gave a positive signal for the indicated 
molecular marker (+) (at 24 hr after injection) are shown. 
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Figure 6. Pax3-Dependent Transrepression of the MBP Promoter 
(A) Minimizing the effector to reporter ratio. N-2A neuroblastoma cells 
(2 x 104 cells in 6 cm dishes) were transiently cotransfected with 5 
~g of effector plasmid (CMV-Pax3 or CMV-only) and increasing 
amounts of reporter piasmid (MBP-lacZ). A 1:10 ratio was the lowest 
ratio that gave significant transrepression. 
(B) Pax3 transrepresses the MBP promoter, but Pax6 does not. N-2A 
neuroblastoma ceils were cotransfected ata 1:10 ratio (0.5 I~g:5 I~g) 
of effector (CMV-Pax3, CMV, and CMV-Pax6) to reporter (MBP-lacZ 
and RSV-IacZ) as indicated. Each dish was harvested 48 hr after 
transfection and assayed for I~-galactosidase activity. Each bar shows 
the average and SD of reporter activity from three parallel transfections 
(Unit = A420 x 108/240 min x ce~l number). 
nificantly reduced the MBP reporter activity at ratios as 
low as 0.1 (Figure 6A). The CMV-Pax6 effector was unable 
to reduce MBP-lacZ reporter activity even at ratios as high 
as 0.4 (data not shown). No effectors could reduce RSV- 
lacZ reporter activity at any ratio (data not shown). 
A 1:10 ratio of CMV-Pax3 to MBP-lacZ cotransfected 
into neuroblastoma cells (N-2A) gave a 23-fold lower re- 
porter signal than parallel cotransfections utilizing the 
CMV-only or CMV-Pax6 effectors (Figure 6B). In parallel, 
the RSV-lacZ signal was the same with all three effector 
plasmids (Figure 6B), indicating that Pax3 does not act 
as a general repressor of all reporters. These results are 
consistent with the model that Pax3 represses the MBP 
promoter. Furthermore, the cis-acting elements within the 
1.3 kb MBP promoter fragment examined can mediate at 
least some of the Pax3-dependent repression of endoge- 
nous MBP observed in microinjection experiments. 
Discussion 
Pax3 during Myelination 
A number of observations implicate Pax3 in the differentia- 
tion of eSCs into mSCs and nmSCs. Pax3 RNA was down- 
regulated when eSCs differentiated to the myelin type but 
continued to be expressed in the nonmyelin type. Simi- 
larly, N-CAM, L1, GFAP, and NGFR are also turned off 
in mSCs and remain on in nmSCs. Thus, both Pax3 and 
these markers of eSCs or nmSCs are down-regulated ur- 
ing myelination, both in development and during regenera- 
tion. The majority of eSCs terminally differentiate to mSCs 
in a prolonged process that begins several days after birth. 
The first MBP-positive cells were detected at P5. Pax3 
may be involved in maintaining the molecular phenotype 
of eSCs in some glial cells of the adult PNS. In sciatic 
nerve crushing, Pax3 RNA expression is induced in the 
demyelinating distal nerve stump in a new"eSC-like" popu- 
lation of cells. It is not clear whether these eSC-like cells 
are derived from nmSCs transiently proliferating to replace 
dying mSCs or from mSCs that have lost their myelin, tn 
late stages of nerve regeneration, the eSC-like cell popula- 
tion terminally differentiates to mSCs in a process appar.. 
ently recapitulating development. 
The ability of undifferentiated glial cells to adhere to 
neurons may depend on expression of adhesion mole- 
cules such as N-CAM. Homeobox-containing proteins are 
directly involved in the control of transcription of these 
molecules (Edelman and Jones, 1992). If Pax3 were in- 
volved in maintaining the expression of adhesion mole- 
cules, cells with dysfunctional Pax3 could no longer ad 
here to the proper surfaces (e.g., axons). Thus, they could 
not receive the normal inductive signals (e.g., from the 
axons) required for further proliferation, and eventtally 
differentiation. N-CAM and NGFR were both expressed 2 
days after Pax3 in nerve regeneration, suggesting that 
these genes may be positively regulated targets of Pax& 
MBP would provide an example of a negatively regulated 
target. 
Pax3 binding could be demonstrated for sequences of 
the N-CAM promoter (Chalepakis et al., 1994b). Similarly, 
Pax3 specifically binds in vitro to a region 1.1 kb upstream 
of the MBP cap site (data not shown). However, we found 
it surprising that five out of the six marker proteins we 
assayed specifically responded to Pax3 in microinjection 
experiments. Although direct gene regulation by Pax3 
binding to all five promoters is possible, other models 
should not be excluded at this stage. 
Pax3 RNA is detected in astrocytes but not in oligoden- 
drocytes of the CNS (Kioussi and Gruss, 1994). These two 
cell types are nonmyelinating and myelinating, respec- 
tively. Thus, Pax3 RNA expression follows a similar pattern 
during genesis of myelinating celt types in both the CNS 
and PNS. In both systems, Pax3 may help to maintain 
cells in a nonmyelinating state. 
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A Gap in Pax3 RNA Expression 
The expression pattern of Pax3 RNA is biphasic with re- 
spect to the SC lineage. In the first phase (until E13.5), 
Pax3 may play a role in the establishment and mainte- 
nance of eSCs. The patterning of limb and body is largely 
complete by E13.5. Cartilaginous precursors of the skele- 
ton can be identified at this stage, and the innervation of 
the PNS is laid out. The second phase (E18.5 to P5) begins 
in eSCs with weak Pax3 RNA expression 1 day before 
birth, followed by a dramatic Pax3 RNA induction at birth. 
In the 5 days between the two phases of Pax3 RNA expres- 
sion, eSCs rapidly proliferate as the embryo enlarges 
quickly. Although organogenesis occurs in this time span, 
the basic layout of the remaining body does not change 
drastically. 
Although Pax3 RNA and MBP expression are inversely 
correlated during terminal differentiation (myelination), 
MBP is not always on when Pax3 RNA is absent. MBP is 
absent in eSCs between E13.5 and E18.5, the time be- 
tween the two Pax3 RNA expression phases. Thus, MBP 
promoter activity either is repressed by another factor that 
is absent during terminal differentiation or requires an acti- 
vating factor during myelination that is missing between 
E13.5 and E18.5. 
Three Switches in Pax3 RNA Expression 
The expression analysis demonstrated that Pax3 RNA ex- 
pression was switched on or off at least three times in 
the maturation of SCs of the PNS. The eSC population at 
E13.5 was small relative to the number of axons. A few 
round S-100-positive, Pax3 RNA-positive cells accumu- 
lated on axons bundles, and some had short cytoplasmic 
projections. Between E13.5 and birth, the projections 
lengthened, and the ratio of eSCs to axons increased ow- 
ing to rapid proliferation. Pax3 RNA was turned off, but 
S-100 remained on. Near birth, Pax3 RNA was turned on 
again in the S-100-positive SC population just before the 
onset of terminal differentiation (myelination). The firs', 
mSCs were detected -5  days later. Thus, the signal that 
induced Pax3 RNA expression around birth likely pre- 
ceded the signal for myelinating. The third switch in Pax3 
RNA expression occurs only in mSCs during terminal c'if- 
ferentiation, when Pax3 RNA is turned off. If an eSC re- 
ceives no signal for myelinating, Pax3 RNA remains on 
as that cell becomes an adult nmSC. 
The first two switches in Pax3 RNA expression correlate 
with changes in the proliferative rate of eSCs during devel- 
opment. It is unclear whether reduced Pax3 RNA expres- 
sion is caused by, is an effect of, or is unrelated to in- 
creased proliferation. However, paired domain proteins 
may have roles in controlling cell proliferation. Overex- 
pression of Pax genes results in deregulation of growth 
control (Maulbecker and Gruss, 1993; Stuart et al., 1995). 
The third switch in Pax3 RNA expression occurred dur- 
ing terminal differentiation of mSCs. The "signal" for my- 
elinating (not yet identified) comes from the axon and can 
be delivered only if the axon has continuity with the SC 
perikaryon. Those SCs whose perikarya make close con- 
tact with axons transmitting the signal begin terminal dif- 
ferentiation. Some eSC or eSC-like cells do not receive 
the signal, and they remain in the nonmyelinating state. 
Prior to terminal differentiation, axon-associated SCs 
proliferate and express NGF and NGFR (Taniuchi et al., 
1986). Similarly, the rate of synthesis of NGF and NGFR by 
eSC-like cells is high during regeneration, before axonal 
contact with the target tissue is reestablished (Taniuchi 
et al., 1988). Thus, NGF and its receptor are present in 
SCs until nerve innervation, in development or repair, is 
complete. The signal for myelinating from the axons would 
be sent at this time. 
In the neuron-like PC12 cell line, NGF binding to NGFR 
can initiate a signal transduction cascade, one outcome 
of which is the elevation of intracellular cAMP levels (Knip- 
per et al., 1993). During the NGF-dependent transdifferen- 
tiation of chromaffin cells to sympathetic neurons, artificial 
elevation of intracellular cAMP levels antagonizes the ef- 
fects of NGF during an initial proliferative phase, but pro- 
motes the neuronal phenotype after cells withdraw from 
the cell cycle (Herman et al., 1993). NGF treatment of 
neuronal cell cultures also leads to a transient elevation 
of Pax3 RNA (Kioussi and Gruss, 1994) and c-Jun (Matsu- 
shima and Bogenmann, 1993). It will be of interest o deter- 
mine whether SCs also respond to NGF in a proliferation- 
dependent manner and in which situations this leads to 
an elevation of intracellular cAMP and the expression of 
Pax3 RNA and c-Jun. 
Forskolin treatment artificially raises intracellular cAMP 
levels. Treatment of cultured SCs with forskolin sup- 
presses nmSC marker proteins such as NGFR, N-CAM, 
L1, GFAP, Ran-l, and 04 and induces myelin-specific pro- 
teins such as MBP, P0, and proteolipid protein (PLP) (Jes- 
sen and Mirsky, 1991). c-Jun (Bohman et al., 1987; Bharu- 
cha et al., 1994) and Pax3 RNA are also down-regulated 
by forskolin in this system. Thus, elevating intracellular 
cAMP in cultured SCs leads to repression of certain imme- 
diate-early and nonmyelin genes and leads to induction 
of myelin-specific genes. It will be of interest o determine 
whether cAMP elevation actually occurs in SCs as a result 
of the signal for myelinating in vivo. 
Experimental Procedures 
Antibodies 
Rabbit polyclonal antibodies against S-100 (Sigma), a SC marker; 
GFAP (Sigma), a nmSC marker; and MBP (Dakopatts, Denmark), a
mSC marker, were used at 1:100 dilution. Detection antibodies such 
as 5(6)-carboxy-fluorescein-N-hydroxysuccinimide ester (FITC) conju- 
gated to anti-digoxigenin sheep F(ab') fragments (Boehringer Mann- 
helm Corp.) and tetramethylrhodamine B isothiocyanate (TRITC) con- 
jugated to goat antibody against rabbit IgG (Sigma) were used at 
1:500 and 1:100 dilution, respectively. 
Other Materials 
Transferrin, selenium, putrescine, triiodothyronine, thyroxine, dexa- 
methasone, insulin, cytosine arabinoside, forskolin, laminin, poly-L- 
lysine, fetal calf serum, DMEM F-12 Ham, and o-Nitrophenyl-~-D- 
galactopyranoside (ONPG) were obtained from Sigma; tribromoethyl 
alcohol was obtained from Aldrich; and tertiary amyl alcohol was ob- 
tained from Merck. 
Defined Medium 
Defined medium consisted of DMEM F-12 Ham with (final concentra- 
tion in parentheses) transferrin (100 mg/ml), progesterone (60 ng/ml), 
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putrescine (16 Ilg/ml), insulin (5 ~.g/ml), thyroxine (0.4 ~.g/ml), selenium 
(160 ng/ml), triiodothyronine (10 ng/ml), dexamethasone (40 ng/ml), 
penicillin (100 IU/ml), streptomycin (100 IU/ml), glutamine (2 mM), and 
10% heat~inactivated fetal calf serum. 
Schwann Cell Cultures 
SC cultures were prepared essentially as described previously (Kioussi 
et al., 1992). Briefly, sciatic nerve from E14.5 and P5 mice was dis- 
sected, chopped, and incubated in 400 p.I of enzyme solution con- 
taining collagenase (0.2%) and trypsin (0.125%) for 45 rain at 37°C. 
After centrifugation, the cells were resuspended in medium, counted, 
and plated at a density of 3000 cells per coverslip in a 20 I~1 drop 
on poly-L-lysine/laminin-coated coverslips. After 3 hr, cultures were 
covered with 180 I~1 of medium. For tong-term dissociated SC cultures, 
24 hr after plating the cells were treated with 10 I~M cytosine arabino- 
side for 24 hr to kill dividing cells, and the cells were grown in serum- 
free medium. In some experiments, forskolin (2 ~M; Lemke and Chao, 
1988), a reversible activator of adenyl cyclase, was added to cells 
cultured in media for 48 hr. Ceils were washed, cultured in serum-free 
defined medium for 24-48 hr, and microinjected. After a further 24 
hr, injected cells were fixed and analyzed. 
Microinjections 
After treatment with forskolin, SCs were microinjected with SV40 pro- 
moter Pax3, SV40 promoter control plasmid (150 ng/ml), or Tris-EDTA 
buffer. Microinjections were performed in a Zeiss Axiophot reverse 
microscope using the Eppendorf microinjector 6242 (manual pressure 
[P2] 400-500 hPa and constant pressure [P3] 90-100 hPa). Glass 
capillaries (GC 120F-10, CLARK Electronic Instruments) were filled 
with 0.5-1 p.I of DNA solution, and 20-30 cells were microinjected per 
capillary. 
Sciatic Nerve Transection and Crush 
NMRI mice (3-week-old) were anesthetized with 0.015 ml per gram 
of body weight avertin (8% tribromoethyl alcohol, 4% tertiary amyl 
alcohol), and the left sciatic nerve was aseptically transected 1-3 mm 
below the sciatic notch. To prevent regrowth into the distal stump, 3 
mm of the proximal side was removed. The contralateral sciatic nerve 
served as control. Nerve crush was performed by tightly compressing 
the sciatic nerve at the sciatic notch with flattened forceps twice, each 
time for 10 s. This technique causes all axons to degenerate, but 
allows axonal regeneration. At 4, 7, 15, and 30 days after injury, the 
animals were killed by cervical dislocation, and both sciatic nerves 
were immediately removed for in situ analysis. 
Teased Nerve Preparations 
Sciatic nerves from mice of various ages were excised, placed in ice- 
cold PBS, and partially teased into bundles and individual fibers using 
fine needles on gelatin-coated microscope slides. Samples were al- 
lowed to dry before double-labeling in situ hybridization. 
Double-Labeling In Situ Hybridization 
Cells grown on coverslips and teased nerve preparations were pre- 
pared for immunofluorescent double labeling for Pax3 RNA and differ- 
ent protein markers as described by Kioussi and Gruss (1994). Briefly, 
cells and teased nerves were fixed with 40/0 paraformaldehyde inPBS, 
rinsed in PBS prehybridized for 3 hr in a humid 45°C chamber, and 
washed successively at room temperature for 2 min in 70%, 90%, and 
100% ethanol. Digoxigenin*labeled Pax3 RNA probe was synthesized 
using T7 polymerase. Preparations were hybridized for 16 hr. For im- 
munofluorescent double labeling, preparations were incubated with 
primary antibodies for 2 hr and rinsed before applying both secondary 
antibodies for 2 hr at room temperature. Immunofluorescence-stained 
preparations were viewed with a Zeiss Axiophot photomicroscope. 
Unless otherwise stated, photographic prints referring to comparative 
immunostaining were prepared under identical conditions. 
DNA Transfections and ~Galactosidase Assays 
N-2A (neuroblastoma) cells were cultured in DMEM supplemented 
with 10% fetal calf serum. Cells (2 x 104) were transfected with DNA 
using the calcium phosphate precipitation technique (Graham and van 
tier Eb, 1973). At 12 hr after addition of the precipitate, the medium 
was removed, cells were washed 3 times with PBS, and fresh medium 
was added. Cells were harvested at 48 hr after addition of the precipi- 
tate and suspended in 100 ~.1 of TEN buffer (40 mM Tris-HCI [pH 7.5], 
1 mM EDTA, 150 mM NaCI), Cells were disrupted by freeze-thaw (3 
times at -100°C and 37°C) and microfuged to remove debris. Extract 
(30 ~1) was added to 1 ml of ~-galactosidase assay buffer (60 mM 
Na2HPO4, 40 mM NaH2PO,, 10 mM KCI, 1 mM MgCI2, 50 mM ~-mercap- 
toethanol). The enzymatic reaction was started with 200 p.I of ONPG 
(4 mg/ml in 60 mM Na2HPO4, 40 mM NaH2PO4 [pH 7.0]), incubated 
at 37°C for 4 hr, and stopped with 500 ~1 of 1 M Na2CO3. Absorbance 
was measured at 420 rim, and activity was normalized by the number 
of cells per transfected ish (Unit = A,2o x 108/240 minx cell number). 
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